For example, c-REL may be a suitable target for GC tumours with strong NF-κB pathway activity, RELA for plasmablast-associated tumours, and RELB and/or NF-κB2 for the subset of DLBCL cases with nuclear translocation of these subunits. The gene discussed is REL; the disease is neoplasm.